Anbio Biotechnology: Improved Margins, Still Priced For Growth That Isn't Showing Up [Seeking Alpha]
Anbio Biotechnology - Class A Ordinary Shares (NNNN)
Company Research
Source: Seeking Alpha
In practice, this has improved near-term operating metrics, but their topline has decreased as well, so it's not a major win in the bigger picture. NNNN sells portable IVD platforms (FIA, LFIA, LAMP, RT-PCR, ChLIA, and dry chemistry) with broad disease coverage but lacks a near-term catalyst. Europe remains its core market. Other regions contribute less, and I don't see an upcoming “franchise” product or model that could trigger a growth spurt. So, on balance, I still think NNNN's valuation looks excessively stretched. It's priced for substantial growth yet has no clear catalysts for that. Hence, I remain bearish. Morsa Images/DigitalVision via Getty Images Anbio Biotechnology ( NNNN ) is a medical device company that develops in vitro diagnostics (IVD) solutions. Lately, the company appears to be prioritizing profitability, choosing higher margins over higher sales volume. They've also made some governance changes and replaced auditors This article was written by Analy
Show less
Read more
Impact Snapshot
Event Time:
NNNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NNNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NNNN alerts
High impacting Anbio Biotechnology - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NNNN
News
- Anbio Biotechnology (NASDAQ:NNNN) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- Anbio Biotechnology (NASDAQ:NNNN) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d+)" rating on the stock.MarketBeat
- Anbio Biotechnology's (NASDAQ:NNNN) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? [Yahoo! Finance]Yahoo! Finance
NNNN
Sec Filings
- 2/17/26 - Form 6-K
- 1/26/26 - Form 6-K
- 12/30/25 - Form 6-K
- NNNN's page on the SEC website